When: Pullback to $1,140-$1,150 with RSI>40

Then: 1/3-size add

HOLD; trim into $1,175-$1,180 resistance; add half-size only on confirmed close below $1,070 with positive MACD divergence

• Stock closed below 50 SMA at $1,177, 10 EMA at $1,167, and VWMA at $1,159 all on same session — three bearish momentum signals simultaneously
• 9/30 candle opened at $1,186, hit $1,214, closed at $1,157 — massive intraday reversal on above-average volume of 3.4 million shares indicating distribution signature
• MACD at -0.05 with signal at -4.36 and histogram at +4.31 — weakest possible bullish crossover, not momentum conviction but exhaustion
• Forward P/E of 24.4x depends on 59% EPS expansion embedded in consensus forecasts which are subject to revision in higher-rate environment
• 30-year yield at highest level since 2002 means discount rate on future cash flows increased materially, threatening the 437% multiple expansion over five years
• Goodwill spiked $14.6 billion in single quarter and net debt jumped from $39 billion to $46 billion year-over-year, with Q2 showing $8.75 billion acquisition — aggressive capital deployment at $1.05 trillion market cap
• Oral GLP-1 race poses structural threat: NVO oral semaglutide, Viking oral candidate, and AstraZeneca Phase 3 all threaten injectable franchise even if Zepbound wins head-to-head trials
• Entry plan at $1,070 (200 SMA) with stop at $1,000 and half-size position provides asymmetric risk-reward; buying at $1,157 pays full price for unconfirmed setup with wider dollar stop

→ vs aggressive: Technical setup is distribution signature, not profit-taking consolidation — three momentum gauges flashing bearish simultaneously on high volume is supply overwhelming demand, not coiled energy

→ vs aggressive: MACD crossover is weakest possible bullish signal at -0.05 with histogram barely positive at +4.31 — this is momentum exhaustion, not a buy signal worth chasing

→ vs aggressive: Defensive franchise insulation from yields works in normal regimes, but 2002-high yields threaten the multiple expansion that drove 437% gains; saying 'it's not Tesla' doesn't prevent de-rating

→ vs aggressive: M&A optionality framed as call option is actually the single biggest idiosyncratic risk — $8.75B acquisition in one quarter with goodwill up $14.6B at stretched multiples historically destroys value

→ vs aggressive: Pie-growing argument misses that LLY's slice could shrink even in growing market if oral GLP-1s capture injectable share — structural modality risk is not visible in momentum indicators

→ vs aggressive: Waiting for $1,070 is disciplined risk management, not performance anxiety — half-size entry at 200 SMA with defined stop is textbook asymmetric risk-reward, while buying now pays retail for institutional signal not yet confirmed

HOLD with active tiered scaling plan

• Maintain core position unchanged for full upside participation on pipeline catalysts
• Tactical add at $1150-$1140 sized at one-third of normal starter with tight stop at $1090
• If stock breaks down through $1100, do not add—wait instead
• Half-size add at $1070 with expanding positive MACD histogram as margin of safety hedge
• Trim 20-25% of position into any test of $1175-$1180 that fails
• Do NOT trim on confirmed breakout above $1180 with volume
• Consider pairing with NVO or healthcare ETF hedge to manage GLP-1 thesis concentration risk
• Current fundamentals: 47.6% YoY revenue growth, 102% ROE, 24.4x forward P/E, $11B TTM free cash flow with 33% net margins
• Q2 M&A added $8.75B acquisition, pushed goodwill up $14.6B, net debt from ~$39B to $46B (18% increase)
• 9/30 candle: opened at 1186, hit 1214, closed at 1157—4.7% intraday reversal on 3.4 million shares signals supply at higher prices

→ vs aggressive: 9/30 candle analysis conflates timeframes—the 4.7% intraday reversal on 3.4M shares signals supply showing up at higher prices, not coiling energy

→ vs aggressive: M&A call option argument is dangerous—Q2 $8.75B acquisition already used the optionality; goodwill up $14.6B, net debt up 18% means they are now in integration mode, not pre-acquisition optionality mode

→ vs aggressive: 24.4x forward P/E argument is circular—59% EPS expansion is embedded in consensus and can be revised down in higher-rate environments

→ vs conservative: 1070 trigger with MACD divergence is late-cycle confirmation chasing—will miss the bounce back to $1150 in days, not weeks

→ vs conservative: M&A treatment too one-sided—strategic M&A in pharma can reinforce pipelines and improve long-term ROIC if assets complement GLP-1 franchise

→ vs conservative: LLY vs Tesla multiple compression comparison is wrong—LLY has $11B TTM FCF with 33% net margins versus Tesla trading on distant optionality with negative cash flow

→ vs conservative: Trim into $1175-$1180 as primary action leaves money on the table if breakout occurs with volume and pipeline catalyst hits